Literature DB >> 14734756

Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I.

Peter K C Goon1, Tadahiko Igakura, Emmanuel Hanon, Angelina J Mosley, Anna Barfield, Amanda L Barnard, Lambrini Kaftantzi, Yuetsu Tanaka, Graham P Taylor, Jonathan N Weber, Charles R M Bangham.   

Abstract

CD4(+) T cells predominate in early lesions in the CNS in the inflammatory disease human lymphotropic T cell virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), but the pathogenesis of the disease remains unclear and the HTLV-I-specific CD4(+) T cell response has been little studied. We quantified the IFN-gamma-producing HTLV-I-specific CD4(+) T cells, in patients with HAM/TSP and in asymptomatic carriers with high proviral load, to test two hypotheses: that HAM/TSP patients and asymptomatic HTLV-I carriers with a similar proviral load differ in the immunodominance hierarchy or the total frequency of specific CD4(+) T cells, and that HTLV-I-specific CD4(+) T cells are preferentially infected with HTLV-I. The strongest CD4(+) T cell response in both HAM/TSP patients and asymptomatic carriers was specific to Env. This contrasts with the immunodominance of Tax in the HTLV-I-specific CD8(+) T cell response. The median frequency of HTLV-I-specific IFN-gamma(+) CD4(+) T cells was 25-fold greater in patients with HAM/TSP (p = 0.0023, Mann-Whitney) than in asymptomatic HTLV-I carriers with a similar proviral load. Furthermore, the frequency of CD4(+) T cells infected with HTLV-I (expressing Tax protein) was significantly greater (p = 0.0152, Mann-Whitney) among HTLV-I-specific cells than CMV-specific cells. These data were confirmed by quantitative PCR for HTLV-I DNA. We conclude that the high frequency of specific CD4(+) T cells was associated with the disease HAM/TSP, and did not simply reflect the higher proviral load that is usually found in HAM/TSP patients. Finally, we conclude that HTLV-I-specific CD4(+) T cells are preferentially infected with HTLV-I.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734756     DOI: 10.4049/jimmunol.172.3.1735

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Interference with immune function by HTLV-1.

Authors:  P K C Goon; C R M Bangham
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

2.  Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion.

Authors:  Priya Kannian; Han Yin; Rami Doueiri; Michael D Lairmore; Soledad Fernandez; Patrick L Green
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death.

Authors:  David Sibon; Anne-Sophie Gabet; Marc Zandecki; Christiane Pinatel; Julien Thête; Marie-Hélène Delfau-Larue; Samira Rabaaoui; Antoine Gessain; Olivier Gout; Steven Jacobson; Franck Mortreux; Eric Wattel
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

4.  Pre-morbid human T-lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive adult T-cell leukemia/lymphoma.

Authors:  Andrew Hodson; Daniel J Laydon; Barbara J Bain; Paul A Fields; Graham P Taylor
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

5.  In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.

Authors:  Hiroya Kobayashi; Toshihiro Ngato; Keisuke Sato; Naoko Aoki; Shoji Kimura; Yuetsu Tanaka; Hitoshi Aizawa; Masatoshi Tateno; Esteban Celis
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

6.  Separate cellular localizations of human T-lymphotropic virus 1 (HTLV-1) Env and glucose transporter type 1 (GLUT1) are required for HTLV-1 Env-mediated fusion and infection.

Authors:  Yosuke Maeda; Hiromi Terasawa; Yuetsu Tanaka; Chisho Mitsuura; Kaori Nakashima; Keisuke Yusa; Shinji Harada
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

7.  Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru.

Authors:  I Best; V Adaui; K Verdonck; E González; M Tipismana; D Clark; E Gotuzzo; G Vanham
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

8.  Genes related to antiviral activity, cell migration, and lysis are differentially expressed in CD4(+) T cells in human t cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.

Authors:  Mariana Tomazini Pinto; Tathiane Maistro Malta; Evandra Strazza Rodrigues; Daniel Guariz Pinheiro; Rodrigo Alexandre Panepucci; Kelen Cristina Ribeiro Malmegrim de Farias; Alessandra De Paula Sousa; Osvaldo Massaiti Takayanagui; Yuetsu Tanaka; Dimas Tadeu Covas; Simone Kashima
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-16       Impact factor: 2.205

9.  Immunogenetics and the Pathological Mechanisms of Human T-Cell Leukemia VirusType 1- (HTLV-1-)Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).

Authors:  Mineki Saito
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-10

10.  Ex vivo analysis of human T lymphotropic virus type 1-specific CD4+ cells by use of a major histocompatibility complex class II tetramer composed of a neurological disease-susceptibility allele and its immunodominant peptide.

Authors:  Hirohisa Nose; Ryuji Kubota; Nilufer P Seth; Peter K Goon; Yuetsu Tanaka; Shuji Izumo; Koichiro Usuku; Yoshiro Ohara; Kai W Wucherpfennig; Charles R M Bangham; Mitsuhiro Osame; Mineki Saito
Journal:  J Infect Dis       Date:  2007-12-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.